Impact of Golimumab SC on Disease Specific and Generic HRQoL in Patients With Moderately to Severely Active UC: PURSUIT-SC Induction
Brian G. Feagan(Western University), William J. Sandborn(University of San Diego), Peter G. Gibson(University Gastroenterology), Gunnar Järnerot(Örebro University Hospital), Colleen Marano(Johnson & Johnson (United States)), Cynthia Guzzo(Janssen (Belgium)), Paul Rutgeerts(KU Leuven), Jean–Frédéric Colombel(Icahn School of Medicine at Mount Sinai), Walter Reinisch(Medical University of Vienna), Judith Collins(Oregon Health & Science University), Jewel Johanns(Johnson & Johnson (United States)), Chenglong Han(Janssen (United States)), Hongyan Zhang(Northwest A&F University), Richard Strauß(Hennepin County Medical Center)
Cited by 2
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k